Primary Outcome Measures:
- Long-term Safety. [ Time Frame: Throughout 2 year treatment period ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Change from baseline in the monthly bleeding score and the number of days with bleeding. [ Time Frame: Each Month ] [ Designated as safety issue: No ]
- Change from baseline in hemoglobin, hematocrit, TIBC, ferritin and iron concentrations. [ Time Frame: Months 3, 6, 9,12,15,18, 24 ] [ Designated as safety issue: No ]
- Percent change from baseline in volume of the largest fibroid. [ Time Frame: Months 12, 24 ] [ Designated as safety issue: No ]
- Change from baseline in bloating, pelvic pressure, dysmenorrhea and urinary symptoms. [ Time Frame: Months 6, 12, 18, 24 ] [ Designated as safety issue: No ]
- Change from baseline in total symptom severity score and the Uterine Fibroid Symptoms-Quality of Life total score. [ Time Frame: Months 6, 12, 18, 24 ] [ Designated as safety issue: No ]
- Change from baseline in the 8 scales of the SF-36 questionnaire. [ Time Frame: Months 6, 12, 18, 24 ] [ Designated as safety issue: No ]
- Change from baseline in the 4 scales and overall index of the Work Limitations Questionnaire. [ Time Frame: Months 6, 12, 18, 24 ] [ Designated as safety issue: No ]
- Cumulative percent of subjects who achieve amenorrhea. [ Time Frame: Each Month ] [ Designated as safety issue: No ]
No medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids in women and many women must resort to surgery for relief. The objective of this study is to determine the long-term safety of two asoprisnil doses (10 and 25 mg tablets) administered daily to women who received asoprisnil in one of the asoprisnil long-term studies (study C03-062 or study M01-391). The safety endpoints for this study will include the affects of asoprisnil on the endometrium, ovaries, bone (a subset of study M01-391 subjects), lipid profiles, adverse events, and changes from baseline lab values and vital signs.
Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was prematurely discontinued for all subjects. To ensure safety, subjects will remain on study and will undergo scheduled study procedures. In most subjects, endometrial changes reversed after asoprisnil discontinuation.